YD Bio management commentary cites larger drug, medical product orders driving H1 2026 revenue up to $0.8 million

In management commentary for the six months ended June 30, 2026, net revenue rose to $846,501 from $204,007.

Management attributed the gain to expanded business with existing clients, higher visibility, and several sizable orders, led by a $327,060 drug order.

Cost of revenue climbed to $578,271 from $135,212, with management citing lower margins on the large order.

Operating expenses increased to $3.5 million from $2.02 million, driven by staffing expansion, marketing spend, professional fees, and R&D tied to licensed patents.

Net income was $6.7 million versus a $1.92 million loss, largely reflecting a $9.85 million gain from warrant liability fair-value changes.